Reports Q3 revenue $1.3B, consensus $1.28B. “Our positive fiscal year 2025 performance continued in the third quarter, with strong top-line revenue growth, margin expansion, and double-digit EPS growth resulting from solid customer demand for our best-in-class products and software solutions,” said Resmed’s (RMD) CEO, Mick Farrell.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed appoints Salli Schwartz as Chief Investor Relations Officer
- ResMed price target lowered to $268 from $280 at KeyBanc
- RMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ResMed price target lowered to $265 from $280 at Mizuho
- Resmed’s Strong Financial Performance and Strategic Growth Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue